Stock-Based Compensation Plans	3 Months Ended
Mar. 31, 2020
Stock-Based Compensation Plans
Stock-Based Compensation Plans	15. Stock-Based Compensation Plans For the three months ended March 31, 2020 and 2019, the Company recognized stock-based compensation expense of $12.5 million and $13.7 million, respectively, resulting from stock options, restricted stock units, performance-based restricted stock units and deferred stock units in the Condensed Consolidated Statements of Income. During the three months ended March 31, 2020, the Company granted 0.5 million options at a weighted-average exercise price of $26.50 and 2.4 million performance-based restricted stock units and restricted stock units at a weighted-average grant date fair value of $25.99. As of March 31, 2020, the Company had 4.9 million outstanding options at a weighted-average exercise price of $19.20, of which 3.8 million options were exercisable at a weighted-average exercise price of $18.42. The Company had 7.2 million performance-based restricted stock units (based on target performance) and restricted stock units at a weighted-average grant date fair value of $20.78 as of March 31, 2020.

Stock-Based Compensation Plans

3 Months Ended

Mar. 31, 2020

15. Stock-Based Compensation Plans

For the three months ended March 31, 2020 and 2019, the Company recognized stock-based compensation expense of $12.5 million and $13.7 million, respectively, resulting from stock options, restricted stock units, performance-based restricted stock units and deferred stock units in the Condensed Consolidated Statements of Income.

During the three months ended March 31, 2020, the Company granted 0.5 million options at a weighted-average exercise price of $26.50 and 2.4 million performance-based restricted stock units and restricted stock units at a weighted-average grant date fair value of $25.99. As of March 31, 2020, the Company had 4.9 million outstanding options at a weighted-average exercise price of $19.20, of which 3.8 million options were exercisable at a weighted-average exercise price of $18.42. The Company had 7.2 million performance-based restricted stock units (based on target performance) and restricted stock units at a weighted-average grant date fair value of $20.78 as of March 31, 2020.